期刊文献+

胸苷酸合成酶基因多态性与不同种族乳腺癌FEC方案化疗不良反应相关性研究 被引量:6

Relationship between polymorphism of thymidylate synthase gene and side effects of FEC regimen for breast cancer patients of different races
下载PDF
导出
摘要 目的了解胸苷酸合成酶基因(TYMS)多态性在乳腺癌患者中的分布及其基因型与化疗不良反应的关系。方法选取雌激素受体基因5'端非编码区的28 bp串联重复序列(VNTR)作为遗传标记,运用PCR-聚丙烯酰胺凝胶电泳分析法对50例白种人和23例亚裔乳腺癌患者进行基因分型,结合患者临床病理特征、FEC化疗不良反应和生存数据进行分析。结果 TYMS 28 bp VNTR基因型在白种人群2R/2R、2R/3R和3R/3R的基因型频率分别为12.0%、62.0%和26.0%,在亚裔人群分别为4.4%、30.4%和65.2%,差异有统计学意义(P<0.05)。TYMS 28 bp VNTR位点的等位基因及基因型与患者组织学类型、组织学分级、淋巴结转移、临床分期、雌激素受体、孕激素受体和人类表皮生长因子受体-2表达等无关。所有患者平均随访时间43.21个月,复发5例,死亡5例;单因素及多因素分析提示TYMS基因型不是影响预后因素。亚裔人群化疗后3-4级白细胞减少症发生率显著高于白种人群(86.96%vs 60.00%,P=0.021);TYMS 28 bp VNTR3R/3R基因型中,3-4级白细胞减少症发生率高于2R/3R、2R/2R,但差异无统计学意义(75.00%vs65.79%,57.14%,P=0.578)。结论白种人与亚裔乳腺癌患者FEC化疗耐受性存在差异,可能与两者TYMS基因28 bp VNTR多态性差异有关。 Objective To explore the distribution of polymorphism of thymidylate synthase (TYMS) gene in breast cancer patients and the relationship between the genotypes and the side effects of chemotherapy. Methods The variable number of tandem repeats (VNTR) in 28 bp of 5′untranslated region (untranslated region, 5′UTR) of TYMS gene was selected as the genetic marker. PCR-nondenaturing polyacrylamide gel electrophoresis was employed to determine the genotype of 50 Caucasian patients and 23 Asian patients with breast cancer and analysis was conducted according to clinical pathological features, side effects of FEC chemotherapy, and survival data of patients. Results The frequencies of genotypes of 2R/2R, 2R/3R, and 3R/3R of TYMS 28 bp VNTR in Caucasian patients were 12.0%, 62.0%, and 26.0%, and in Asian patients were 4.4%, 30.4%, 65.2%, respectively. The differences were statistically significant (P〈0.05). The allclomorphic genes and genotypes of loci of TYMS 28 bp VNTR were irrelevant to histological types, histological grades, lymph node metastasis, clinical stages, estrogen receptor, progenstogen receptor, and human epidermal growth factor receptor 2. The mean time of follow-up was 43.21 months. Five cases relapsed and five patients died. The univariate analysis and multivariate analysis indicated that the genotype of TYMS gene was not a factor that affected the prognosis. After being treated by the chemotherapy, the incidence of leucopenia (grade 3-4) of Asian patients was significantly higher than that of Caucasian patients (86.96% vs 60.00%, P=0.021). The incidence of leucopenia (grade 3-4) of 3R/3R of TYMS 28 bp VNTR was higher than that of 2R/3R and 3R/3R. But the differences were not statistically significant (75.00%, 65.79%, and 57.14%, respectively, P=0.578). Conclusion The tolerability to FEC chemotherapy of Caucasian and Asian breast cancer patients is different. This may be relevant to the polymorphism of 28bp VNTR of TYMS gene.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2014年第6期850-854,共5页 Journal of Shanghai Jiao tong University:Medical Science
基金 苏州市科技计划项目(SYS201062) 上海市浦东新区社会发展局卫生科技项目(DW2007D-4) 上海高校选拔培养优秀青年教师科研专项基金资助项目(jdy09036)~~
关键词 乳腺癌 胸苷酸合成酶基因 多态性 化疗 breast cancer thymidylate synthase gene polymorphism chemotherapy
  • 相关文献

参考文献8

  • 1Nicolson MC,Fennell DA,Ferry D,et al.Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase Ⅱ clinical trial [J].J Thorac Oncol,2013,8(7);930-939. 被引量:1
  • 2Ghosh S,Winter JM,Patel K,et al.Reexamining a proposal:thymidylate synthase 5;-untranslated region as a regulator of transla-tion efficiency[J].Cancer Biol Ther,2011,12(8):750-755. 被引量:1
  • 3Showalter SL,Showalter TN,Witkiewicz A,et al.Evaluating thedrug-target relationship between thymidylate synthase expression andtumor response to 5-fluorouracil:is it time to move forward ? [J].Cancer Biol Ther,2008,7(7):986-994. 被引量:1
  • 4Pullarkat ST,Stoehlmacher J,Ghaderi V,et al.Thymidylatesynthase gene polymorphism determines response and toxicity of5-FU chemotherapy[J].Pharmacogenomics J,2001,1(1):65-70. 被引量:1
  • 5Schwab M,Zanger UM,Marx C,et al.Role of genetic and nonge-netic factors for fluorouracil treatment-related severe toxicity:a pro-spective clinical trial by the German 5-FU Toxicity Study Group[J].J Clin Oncol,2008,26(13):2131-2138. 被引量:1
  • 6Henriquez-Herndndez LA,Murias-Rosales A,Gonzalez-HernandezA,et al.Distribution of TYMS,MTHFR,p53 and MDR1 gene pol-ymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy [J].Cancer Epidemiol,2010,34(5):634-638. 被引量:1
  • 7Kumar K,Vamsy M,Jamil K.Thymidylate synthase gene polymor-phisms effecting 5-FU response in breast cancer patients[J].Cancer Biomark,2010,6(2):83-93. 被引量:1
  • 8Largillier R,Etienne-Grimaldi MC,Formento JL,et al.Pharmaco-genetics of capecitabine in advanced breast cancer patients [J].ClinCancer Res,2006,12(18):5496-5502. 被引量:1

同被引文献59

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部